{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T13:36:01Z","timestamp":1785332161590,"version":"3.55.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,5,7]],"date-time":"2019-05-07T00:00:00Z","timestamp":1557187200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,5,7]],"date-time":"2019-05-07T00:00:00Z","timestamp":1557187200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pharmacol Toxicol"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s40360-019-0303-0","type":"journal-article","created":{"date-parts":[[2019,5,7]],"date-time":"2019-05-07T16:54:02Z","timestamp":1557248042000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Abatacept induced granulomatous hepatitis with a sarcoidosis- like reaction: a blinded trial in mice"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2392-6386","authenticated-orcid":false,"given":"Sultan M.","family":"Almogairen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,5,7]]},"reference":[{"key":"303_CR1","doi-asserted-by":"publisher","first-page":"e0171623","DOI":"10.1371\/journal.pone.0171623","volume":"12","author":"N Balandraud","year":"2017","unstructured":"Balandraud N, Texier G, Massy E, Muis-Pistor O, Martin M, Auger I, et al. Long term treatment with abatacept or tocilizumab does not increase Epstein-Barr virus load in patients with rheumatoid arthritis - A three years\u2019 retrospective study. PLoS One. 2017;12:e0171623.","journal-title":"PLoS One"},{"issue":"2","key":"303_CR2","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.intimp.2015.04.051","volume":"27","author":"K Chaabo","year":"2015","unstructured":"Chaabo K, Kirkham B. Rheumatoid Arthritis-Anti-TNF. Int Immunopharmacol. 2015;27(2):180\u20134.","journal-title":"Int Immunopharmacol"},{"key":"303_CR3","doi-asserted-by":"publisher","first-page":"707","DOI":"10.2147\/CEOR.S115706","volume":"8","author":"MM Bonafede","year":"2016","unstructured":"Bonafede MM, Curtis JR, McMorrow D, Mahajan P, Chen CI. Treatment effectiveness and treatment patterns among rheumatoid arthritis patients after switching from a tumor necrosis factor inhibitor to another medication. Clinicoecon Outcomes Res. 2016;8:707\u201315.","journal-title":"Clinicoecon Outcomes Res"},{"issue":"1","key":"303_CR4","first-page":"1","volume":"68","author":"JA Singh","year":"2016","unstructured":"Singh JA, Saag KG, Bridges SL Jr, Akl EA, Bannuru RR, Sullivan MC, et al. 2015 American College of Rheumatology Guideline for the treatment of rheumatoid arthritis. Arthritis Rheum. 2016;68(1):1\u201326.","journal-title":"Arthritis Rheum"},{"issue":"8","key":"303_CR5","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1007\/s12325-012-0037-5","volume":"29","author":"M Bonafede","year":"2012","unstructured":"Bonafede M, Fox KM, Watson C, Princic N, Gandra SR. Treatment patterns in the first year after initiating tumor necrosis factor blockers in real-world settings. Adv Ther. 2012;29(8):664\u201374.","journal-title":"Adv Ther"},{"issue":"8","key":"303_CR6","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1002\/acr.21663","volume":"64","author":"MM Soliman","year":"2012","unstructured":"Soliman MM, Hyrich KL, Lunt M, Watson KD, Symmons DP, Ashcroft DM. British Society for Rheumatology Biologics Register. Rituximab or a second anti-tumor necrosis factor therapy for rheumatoid arthritis patients who have failed their first anti-tumor necrosis factor therapy? Comparative analysis from the British Society for Rheumatology Biologics Register. Arthritis Care Res. 2012;64(8):1108\u201315.","journal-title":"Arthritis Care Res"},{"issue":"2","key":"303_CR7","doi-asserted-by":"publisher","first-page":"91","DOI":"10.3111\/13696998.2015.1099538","volume":"19","author":"J Harnett","year":"2016","unstructured":"Harnett J, Wiederkehr D, Gerber R, Gruben D, Koenig A, Bourret J. Real-world evaluation of TNF-inhibitor utilization in rheumatoid arthritis. J Med Econ. 2016;19(2):91\u2013102.","journal-title":"J Med Econ"},{"issue":"3","key":"303_CR8","doi-asserted-by":"publisher","first-page":"190","DOI":"10.3109\/03009742.2012.729607","volume":"42","author":"K Chatzidionysiou","year":"2013","unstructured":"Chatzidionysiou K, van Vollenhoven R. Rituximab versus anti-TNF in patients who previously failed one TNF inhibitor in an observational cohort. Scand J Rheumatol. 2013;42(3):190\u20135.","journal-title":"Scand J Rheumatol"},{"issue":"3","key":"303_CR9","first-page":"227","volume":"9","author":"RE Schiotis","year":"2016","unstructured":"Schiotis RE, Buzoianu AD, Mure\u0219anu DF, Suciu S. New pharmacological strategies in rheumatic diseases. J Med Life. 2016;9(3):227\u201334.","journal-title":"J Med Life"},{"issue":"5071","key":"303_CR10","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1126\/science.1496399","volume":"257","author":"PS Linsley","year":"1992","unstructured":"Linsley PS, Wallace PM, Johnson J, Gibson MG, Greene JL, Ledbetter JA, et al. Immunosuppression in vivo by a soluble form of the CTLA-4 T cell activation molecule. Science. 1992;257(5071):792\u20135.","journal-title":"Science."},{"issue":"3","key":"303_CR11","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1590\/S0482-50042010000300014","volume":"50","author":"CE Rodrigues","year":"2010","unstructured":"Rodrigues CE, Vieira FJ, Callado MR, Gomes KW, de Andrade JE, Vieira WP. Use of the abatacept in a patient with psoriatic arthritis. Rev Bras Reumatol. 2010;50(3):340\u20135.","journal-title":"Rev Bras Reumatol"},{"issue":"2","key":"303_CR12","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.reuma.2011.08.002","volume":"8","author":"G Herrero-Beaumont","year":"2012","unstructured":"Herrero-Beaumont G, Mart\u00ednez Calatrava MJ, Casta\u00f1eda S. Abatacept mechanism of action: Concordance with its clinical profile. Reumatol Clin. 2012;8(2):78\u201383.","journal-title":"Reumatol Clin"},{"issue":"2","key":"303_CR13","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1177\/1759720X09360429","volume":"2","author":"R Westhovens","year":"2010","unstructured":"Westhovens R, Verschueren P. The efficacy and safety of abatacept in rheumatoid arthritis. Ther Adv Musculoskelet Dis. 2010;2(2):89\u201394.","journal-title":"Ther Adv Musculoskelet Dis"},{"issue":"Suppl 46","key":"303_CR14","first-page":"S46","volume":"25","author":"J Sibilia","year":"2007","unstructured":"Sibilia J, Westhovens R. Safety of T-cell co-stimulation modulation with abatacept in patients with rheumatoid arthritis. Clin Exp Rheumatol. 2007;25(Suppl 46):S46\u201356.","journal-title":"Clin Exp Rheumatol"},{"issue":"8","key":"303_CR15","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1002\/art.38687","volume":"66","author":"R Alten","year":"2014","unstructured":"Alten R, Kaine J, Keystone E, Nash P, Delaet I, Genovese MC. Long-term safety of subcutaneous abatacept in rheumatoid arthritis: integrated analysis of clinical trial data representing more than four years of treatment. Arthritis Rheum. 2014;66(8):1987\u201397.","journal-title":"Arthritis Rheum"},{"issue":"5","key":"303_CR16","doi-asserted-by":"publisher","first-page":"874","DOI":"10.3109\/14397595.2013.844399","volume":"24","author":"N Iwanaga","year":"2014","unstructured":"Iwanaga N, Origuchi T, Terada K, Ueki Y, Kamo Y, Kinoshita N, et al. Rheumatoid arthritis complicated with severe liver injury during treatment with abatacept. Mod Rheumatol. 2014;24(5):874\u20136.","journal-title":"Mod Rheumatol"},{"issue":"Suppl 2","key":"303_CR17","first-page":"138","volume":"75","author":"N Ruperto","year":"2016","unstructured":"Ruperto N, Lovell DJ, Tzaribachev N, Vega-Cornejo G, Louw I, Berman A, et al. Subcutaneous abatacept in patients with polyarticular juvenile idiopathic arthritis and inadequate response to biologic or non-biologic disease-modifying antirheumatic drugs: pharmacokinetics, efficacy and safety. Ann Rheum Dis. 2016;75(Suppl 2):138.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"303_CR18","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1517\/13543784.2016.1154943","volume":"25","author":"VR Pimentel-Quiroz","year":"2016","unstructured":"Pimentel-Quiroz VR, Ugarte-Gil MF, Alarc\u00f3n GS. Abatacept for the treatment of systemic lupus erythematosus. Expert Opin Investig Drugs. 2016;25(4):493\u20139.","journal-title":"Expert Opin Investig Drugs"},{"issue":"6","key":"303_CR19","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1002\/acr.22786","volume":"68","author":"M Padovan","year":"2016","unstructured":"Padovan M, Filippini M, Tincani A, Lanciano E, Bruschi E, Epis O, et al. Safety of abatacept in rheumatoid arthritis with serologic evidence of past or present hepatitis B virus infection. Arthritis Care Res. 2016;68(6):738\u201343.","journal-title":"Arthritis Care Res"},{"issue":"8","key":"303_CR20","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1002\/acr.21654","volume":"64","author":"PS Kim","year":"2012","unstructured":"Kim PS, Ho GY, Prete PE, Furst DE. Safety and efficacy of abatacept in eight rheumatoid arthritis patients with chronic hepatitis B. Arthritis Care Res. 2012;64(8):1265\u20138.","journal-title":"Arthritis Care Res"},{"issue":"7","key":"303_CR21","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1097\/RHU.0b013e3181f4cd92","volume":"16","author":"TD Mahajan","year":"2010","unstructured":"Mahajan TD, Hooker R, Maher L, Brown G, Reimold A. Abatacept therapy for rheumatoid arthritis in the setting of hepatitis C infection. J Clin Rheumatol. 2010;16(7):332\u20134.","journal-title":"J Clin Rheumatol"},{"issue":"3","key":"303_CR22","doi-asserted-by":"publisher","first-page":"344","DOI":"10.4254\/wjh.v7.i3.344","volume":"7","author":"FD Nard","year":"2015","unstructured":"Nard FD, Todoerti M, Grosso V, Monti S, Breda S, Rossi S, et al. Risk of hepatitis B virus reactivation in rheumatoid arthritis patients undergoing biologic treatment: Extending perspective from old to newer drugs. World J Hepatol. 2015;7(3):344\u201361.","journal-title":"World J Hepatol"},{"key":"303_CR23","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s40360-016-0060-2","volume":"17","author":"R Talotta","year":"2016","unstructured":"Talotta R, Atzeni F, Sarzi PP. Reactivation of occult hepatitis B virus infection under treatment with abatacept: a case report. BMC Pharmacol Toxicol. 2016;17:17.","journal-title":"BMC Pharmacol Toxicol"},{"issue":"4","key":"303_CR24","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.vetpar.2012.12.033","volume":"193","author":"C Strube","year":"2013","unstructured":"Strube C, Heuer L, Janecek E. Toxocara spp. infections in paratenic hosts. Vet Parasitol. 2013;193(4):375\u201389.","journal-title":"Vet Parasitol"},{"issue":"9","key":"303_CR25","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1016\/S0025-6196(12)61578-X","volume":"66","author":"JS Sartin","year":"1991","unstructured":"Sartin JS, Walker RC. Granulomatous hepatitis: a retrospective review of 88 cases at the Mayo Clinic. Mayo Clin Proc. 1991;66(9):914\u20138.","journal-title":"Mayo Clin Proc"},{"issue":"2","key":"303_CR26","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1002\/hep.26709","volume":"59","author":"DE Kleiner","year":"2014","unstructured":"Kleiner DE, Chalasani NP, Lee WM, Fontana RJ, Bonkovsky HL, Watkins PB, et al. Drug-Induced Liver Injury Network (DILIN). Hepatic histological findings in suspected drug-induced liver injury: systematic evaluation and clinical associations. Hepatology. 2014;59(2):661\u201370.","journal-title":"Hepatology."},{"issue":"3","key":"303_CR27","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1002\/hep.24481","volume":"54","author":"A Suzuki","year":"2011","unstructured":"Suzuki A, Brunt EM, Kleiner DE, Miquel R, Smyrk TC, Andrade RJ, et al. The use of liver biopsy evaluation in discrimination of idiopathic autoimmune hepatitis versus drug-induced liver injury. Hepatology. 2011;54(3):931\u20139.","journal-title":"Hepatology."},{"issue":"2","key":"303_CR28","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1002\/cld.301","volume":"3","author":"SA Geller","year":"2014","unstructured":"Geller SA. Autoimmune Hepatitis: Histopathology. Clin Liver Dis. 2014;3(2):19\u201323.","journal-title":"Clin Liver Dis"},{"issue":"7","key":"303_CR29","doi-asserted-by":"publisher","first-page":"876","DOI":"10.5858\/arpa.2014-0214-RA","volume":"139","author":"K Fisher","year":"2015","unstructured":"Fisher K, Vuppalanchi R, Saxena R. Drug-Induced Liver Injury. Arch Pathol Lab Med. 2015;139(7):876\u201387.","journal-title":"Arch Pathol Lab Med"},{"issue":"4","key":"303_CR30","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1007\/s00296-008-0691-8","volume":"29","author":"SK Metyas","year":"2009","unstructured":"Metyas SK, Tadros RM, Arkfeld DG. Adalimumab-induced noncaseating granuloma in the bone marrow of a patient being treated for rheumatoid arthritis. Rheumatol Int. 2009;29(4):437\u20139.","journal-title":"Rheumatol Int"},{"issue":"4","key":"303_CR31","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1007\/s10067-010-1603-3","volume":"30","author":"T Kanellopoulou","year":"2011","unstructured":"Kanellopoulou T, Filiotou A, Kranidioti H, Dourakis SP. Sarcoid-like granulomatosis in patients treated with anti-TNF\u03b1 factors. A case report and review of the literature. Clin Rheumatol. 2011;30(4):581\u20133.","journal-title":"Clin Rheumatol"},{"issue":"5","key":"303_CR32","first-page":"609","volume":"11","author":"S Cathcart","year":"2012","unstructured":"Cathcart S, Sami N, Elewski B. Sarcoidosis as an adverse effect of tumor necrosis factor inhibitors. J Drugs Dermatol. 2012;11(5):609\u201312.","journal-title":"J Drugs Dermatol"},{"issue":"1","key":"303_CR33","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1002\/hep.22322","volume":"48","author":"EM Hennes","year":"2008","unstructured":"Hennes EM, Zeniya M, Czaja AJ, Par\u00e9s A, Dalekos GN, Krawitt EL, et al. International autoimmune hepatitis group. Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology. 2008;48(1):169\u201376.","journal-title":"Hepatology."},{"key":"303_CR34","doi-asserted-by":"crossref","unstructured":"Coash M, Forouhar F, Wu CH, Wu GY. Granulomatous liver diseases: a review. J Formos Med Assoc 2012; 111(1):3-13.","DOI":"10.1016\/j.jfma.2011.11.023"},{"issue":"4","key":"303_CR35","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.arbres.2010.05.011","volume":"47","author":"L Gifre","year":"2011","unstructured":"Gifre L, Ruiz-Esquide V, Xaubet A, G\u00f3mez-Puerta JA, Hern\u00e1ndez MV, Sanmart\u00ed R. Lung sarcoidosis induced by TNF antagonists in rheumatoid arthritis: a case presentation and a literature review. Arch Bronconeumol. 2011;47(4):208\u201312.","journal-title":"Arch Bronconeumol"},{"issue":"3","key":"303_CR36","doi-asserted-by":"crossref","first-page":"232470961772830","DOI":"10.1177\/2324709617728302","volume":"5","author":"U Iqbal","year":"2017","unstructured":"Iqbal U, Siddiqui HU, Anwar H, Chaudhary A, Quadri AA. Allopurinol-Induced Granulomatous Hepatitis: A Case Report and Review of Literature. J Investig Med High Impact Case Rep. 2017;5(3):2324709617728302.","journal-title":"J Investig Med High Impact Case Rep"},{"issue":"1","key":"303_CR37","first-page":"61","volume":"44","author":"KR McMaster 3rd","year":"1981","unstructured":"McMaster KR 3rd, Hennigar GR. Drug-induced granulomatous hepatitis. Lab Investig. 1981;44(1):61\u201373.","journal-title":"Lab Investig"},{"issue":"3","key":"303_CR38","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s12072-017-9793-2","volume":"11","author":"YC Yu","year":"2017","unstructured":"Yu YC, Mao YM, Chen CW, Chen JJ, Chen J, Cong WM, et al. Drug-induced Liver Injury (DILI) Study Group; Chinese Society of Hepatology (CSH); Chinese Medical Association (CMA). CSH guidelines for the diagnosis and treatment of drug-induced liver injury. Hepatol Int. 2017;11(3):221\u201341.","journal-title":"Hepatol Int"},{"issue":"4","key":"303_CR39","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1002\/cld.544","volume":"7","author":"EL Culver","year":"2016","unstructured":"Culver EL, Watkins J, Westbrook RH. Granulomas of the liver. Clin Liver Dis. 2016;7(4):92\u20136.","journal-title":"Clin Liver Dis"},{"issue":"12","key":"303_CR40","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1007\/s005350200180","volume":"37","author":"M Abe","year":"2002","unstructured":"Abe M, Kumagi T, Nakanishi S, Yamagami T, Michitaka K, Abe K, et al. Drug-induced hepatitis with hepatic granuloma due to saridon. J Gastroenterol. 2002;37(12):1068\u201372.","journal-title":"J Gastroenterol"},{"issue":"7","key":"303_CR41","doi-asserted-by":"publisher","first-page":"867","DOI":"10.5858\/arpa.2014-0123-RA","volume":"139","author":"LW Lamps","year":"2015","unstructured":"Lamps LW. Hepatic Granulomas: A Review with Emphasis on Infectious Causes. Arch Pathol Lab Med. 2015;139(7):867\u201375.","journal-title":"Arch Pathol Lab Med"}],"container-title":["BMC Pharmacology and Toxicology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-019-0303-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s40360-019-0303-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-019-0303-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,17]],"date-time":"2024-07-17T18:12:08Z","timestamp":1721239928000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpharmacoltoxicol.biomedcentral.com\/articles\/10.1186\/s40360-019-0303-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,7]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["303"],"URL":"https:\/\/doi.org\/10.1186\/s40360-019-0303-0","relation":{},"ISSN":["2050-6511"],"issn-type":[{"value":"2050-6511","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,7]]},"assertion":[{"value":"16 June 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study protocol was approved by Research Ethics Committee at the College of Medicine, King Saud University, Riyadh. Consent to participate is not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The author declares that there are no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"26"}}